PDF
ZENODO
Published
2025-12-31
Section
Articles
How to Cite
How to Cite
RISK FACTORS AND PREVENTION OF ENDOMETRIAL CANCER
Marufjonova Nozimakhon
Masters of General Oncology Tashkent State Medical University
Azimova Gulcharos
Masters of General Oncology Tashkent State Medical University
Farmonova Malika
Masters of General Oncology Tashkent State Medical University
Keywords: endometrial cancer; obesity; metabolic syndrome; diabetes; unopposed estrogen; polycystic ovary syndrome; Lynch syndrome.
Abstract
Endometrial cancer is the most common gynecological malignancy in many high-income settings, and its global burden is rising. A central reason is that the strongest population-level drivers of risk—excess adiposity and metabolic dysfunction—have become more prevalent in many regions, reshaping both incidence patterns and the age distribution of disease. Current evidence supports a conceptual model in which prolonged exposure of the endometrium to mitogenic signals, especially “unopposed” estrogen and related endocrine-metabolic pathways, increases the likelihood of precursor lesions and malignant transformation. This model explains the contribution of obesity, insulin resistance, type 2 diabetes, anovulation and polycystic ovary syndrome, exogenous estrogen without adequate progestin protection, and certain medications such as tamoxifen. In parallel, a smaller but clinically crucial proportion of cases arises from inherited cancer predisposition syndromes, most prominently Lynch syndrome, which demands tailored preventive strategies that differ from those used in the general population.
References
1. Crosbie E.J., Kitson S.J., McAlpine J.N., Mukhopadhyay A., Powell M.E., Singh N. Endometrial cancer // The Lancet. — 2022. — Vol. 399, № 10333. — P. 1412–1428. — DOI: 10.1016/S0140-6736(22)00323-3. PubMed
2. Concin N., Matias-Guiu X., Vergote I., et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma // International Journal of Gynecological Cancer. — 2021. — Vol. 31, № 1. — P. 12–39. — DOI: 10.1136/ijgc-2020-002230. PubMed
3. Collaborative Group on Epidemiological Studies on Endometrial Cancer. Endometrial cancer and oral contraceptives: an individual participant meta-analysis of 27 276 women with endometrial cancer from 36 epidemiological studies // The Lancet Oncology. — 2015. — Vol. 16, № 9. — P. 1061–1070. — DOI: 10.1016/S1470-2045(15)00212-0. PubMed
4. Practice Bulletin No. 149: Endometrial cancer // Obstetrics & Gynecology. — 2015. — Vol. 125, № 4. — P. 1006–1026. — DOI: 10.1097/01.AOG.0000462977.61229.de. PubMed
5. WHO Classification of Tumours Editorial Board. Female Genital Tumours. 5th ed. — Lyon: International Agency for Research on Cancer, 2020.
6. Lim N., Hickey M., Young G.P., Macrae F.A., Kelly C. Screening and risk reducing surgery for endometrial or ovarian cancers in Lynch syndrome: a systematic review // International Journal of Gynecological Cancer. — 2022. — Vol. 32. — P. 646–655. — DOI: 10.1136/ijgc-2021-003132.
7.
